fonda, page-25

Q2 FY 13 Reddy's reported a 28% Share of the total market

Q3 FY 12 Reddy's report a 30% share of the total market ( quoted from NOV- 12

However In the earnings transcript FEB-13, it's been quoted that market share is now 29%...

So to start with, regardless of where the improvement to market share have come from, there's little improvement from Q2 anyway.

Obviously there were some gains made between the start of Q2 and the end, however it seems little gains have been made during Q3

To back this statement up, here's a quote from the Q2 transcript- "the market has broadly settled down between the innovator,authorized generics and us. So at this juncture, I think the share between the three is more or less settled down"

We've been told to expect further improvements in the hospital sector- back in October PS was quoted in saying "We will be able to see growth because we are getting the cost of manufacturing the drug down all the time, and we're going to be getting more share of the hospital sector,"( So There goes your indication), therefore there's nothing wrong with me presuming the small gains we've had during the quarter have come from hospital sales.

So frankj, please tell me how my comments regarding the likelihood that ACL is relying on improvements to yield as opposed to improvements in market share last quarter, is down ramping? I would also appreciate it if every person who gave frankj a thumb up could explain aswell.